StocksMedium•11 November 2026•
1 min read
Health Catalyst Lowers Full-Year 2026 Revenue Guidance
Key Facts
1Health Catalyst reduced its full-year 2026 revenue guidance.
2The company reported a sharp sequential decline in expected third-quarter revenue.
Health Catalyst reduced its full-year 2026 revenue guidance. Benzinga reported that the company noted a sharp sequential decline in expected third-quarter revenue, highlighting persistent growth challenges despite beating bottom-line estimates.
The guidance reduction follows a reported 26.3% year-on-year revenue contraction in the third quarter. HCAT closed at $1.44 on November 10, 2026, having traded between a session low of $1.35 and a high of $1.53.